Overview

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).

Phase:

PHASE1

Details

Lead Sponsor:

AbbVie

Treatments:

Botulinum Toxins, Type A